CAL
PRDS

Capital Advisors Ltd’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Capital Advisors Ltd’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-151
Closed – – 1759
2022
Q3 		$0 Buy
+151
New +$450 ﹤0.01% 1621

Other funds holding PRDS

FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VS
VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

Capital Advisors Ltd's PRDS Position: Q4 2022 in Review

Capital Advisors Ltd sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q4 2022, closing a stake of 151 shares.

Capital Advisors Ltd first reported a position in PRDS in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 65 funds tracked by Wall St. Rank hold PRDS as of Q4 2022.

  • Capital Advisors Ltd reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Capital Advisors Ltd sold 151 Pardes Biosciences, Inc. Common Stock shares in Q4 2022.
  • Capital Advisors Ltd first reported a position in Pardes Biosciences, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Capital Advisors Ltd's Pardes Biosciences, Inc. Common Stock position peaked at $0 in Q3 2022.
  • 65 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q4 2022.

Based on Capital Advisors Ltd's 13F filing for Q4 2022, filed 7 Feb 2023.